Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 710

Results For "RI"

11152 News Found

Sun Pharma included in S&P Global Sustainability Yearbook 2024
Sustainability | February 13, 2024

Sun Pharma included in S&P Global Sustainability Yearbook 2024

This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses


Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar
Healthcare | February 13, 2024

Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar

Launches collaborative centre for translational research in head and neck cancer


Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg
Drug Approval | February 10, 2024

Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions


Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
News | February 10, 2024

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024


Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur
News | February 10, 2024

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur

The 200 bedded hospital owned & operated by Alexis


Zydus Lifesciences Q3 FY24 PAT up 26.8%
News | February 10, 2024

Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.


Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline
News | February 09, 2024

Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline

Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement


Growth of Ayush sector is bound to happen: Kotecha
Policy | February 09, 2024

Growth of Ayush sector is bound to happen: Kotecha

Ayush is expanding beyond wellness to therapeutic wellness


Qure.ai adds new FDA breakthrough device status for qSpot-TB
Digitisation | February 09, 2024

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months